NCT02193191View on ClinicalTrials.gov

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 17, 2014

Primary Completion Date

March 27, 2025

Study Completion Date

March 27, 2025

Conditions
Sickle Cell Disease
Interventions
DRUG

Plerixafor

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical College, New York

Sponsors

Collaborators (2)

Sanofi
Duke University
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

New York Blood Center

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Duke University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER